Compare Tenet Healthcare Corporation (THC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Tenet Healthcare (THC) trades at $266.91, down 0.69% on the day, with strong fundamental performance including three consecutive quarterly earnings beats. The stock maintains bullish technical signals with key support at $265 and resistance at $271. Revenue growth continues despite softer surgical volumes, driven by higher revenue per case and favorable service mix. Analyst consensus remains overwhelmingly positive with 81% buy ratings and a $283.36 price target representing 6% upside potential.

THC presents a compelling investment case with attractive valuation metrics (P/E 10.5, EV/EBITDA 5.91) and strong profitability (ROE 53.31%, net margin 9.9%). The company's expanding capital-return strategy is supported by robust cash flow, though growth investments and capital needs require monitoring. Key risks include execution challenges and healthcare regulatory uncertainty, but the fundamental outlook remains positive with expected revenue growth to $22.6B and net profit margin expansion to 9.89% in 2026.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.